Evidence map›Paper›PMID 37580265›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Research progress on the role of type II innate lymphoid cells in liver diseases].

M K Yu, Y J Zhu, J B Ding, F B Zhang, X B Lu

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M K YuDepartment of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.
Y J ZhuReproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
J B DingDepartment of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.
F B ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
X B LuDepartment of infection, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.

Funding

National Natural Science Foundation of China 82060115, 81960373
6 · The paper itself

Abstract

Type II innate lymphoid cell (ILC2) is a newly identified innate immunological cell that belongs to the lymphocyte lineage in cell morphology, resides in the body's mucosal tissues, and has the dual functions of innate and adaptive immunity to promote tissue remodeling and repair after injury. Additionally, it is involved in the occurrence and development of a variety of liver diseases and plays an important role in maintaining the immunological homeostasis of the liver region. This article reviews the differentiation, development, and biological functions of ILC2, with particular attention to the research progress in liver diseases.

Indexed as

Immunity, InnateLiver DiseasesCell DifferentiationHumansLymphocytesInnate immunityLiver diseasesProgressType II innate lymphocytes

Identifiers

PMID37580265
PMCPMC12814541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.